Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro - PubMed (original) (raw)
. 1994 Jun 1;54(11):3066-71.
Affiliations
- PMID: 8187097
Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro
A Stahl et al. Cancer Res. 1994.
Abstract
Previously, we reported that urokinase-type plasminogen activator (uPA) plays a pivotal role in extracellular matrix dissolution by malignant melanoma cells. Here, we demonstrate that a highly metastatic melanoma cell line (M24met) that secretes uPA expresses high levels of the uPA receptor (uPAR), 2.4 x 10(6) binding sites/cell with a KD of 5.67 x 10(-10) M. The receptor was identified as a 55,000-60,000 kDa cell surface protein. Although M24met cells secrete uPA, they are unable to efficiently utilize this enzyme for invasion, unless it is bound to its receptor. This contention is based on the finding that an antibody against uPAR (monoclonal antibody 3936) inhibited invasion of M24met cells through a reconstituted basement membrane (Matrigel) up to 33%, while a reduction of uPA catalytic activity by its plasminogen activator inhibitor-2 resulted in 46% inhibition of invasion. Furthermore, uPAR is involved in signal transduction events in M24met cells, since both uPA and its amino-terminal fragment stimulated the migration of melanoma cells toward Matrigel, resulting in maximal increases of 32 and 72%, respectively. Our results indicate that both uPA and uPAR are involved in melanoma metastasis and that uPAR contributes to at least two important steps in this process, matrix dissolution and migration.
Similar articles
- Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM. Bauer TW, et al. Cancer Res. 2005 Sep 1;65(17):7775-81. doi: 10.1158/0008-5472.CAN-05-0946. Cancer Res. 2005. PMID: 16140945 - Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line.
Karikó K, Kuo A, Boyd D, Okada SS, Cines DB, Barnathan ES. Karikó K, et al. Cancer Res. 1993 Jul 1;53(13):3109-17. Cancer Res. 1993. PMID: 8391387 - Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V, Bürgle M, de Prada NA, Schmiedeberg N, Riemer C, Schroeck F, Kellermann J, Degitz K, Wilhelm OG, Schmitt M, Kessler H. Magdolen V, et al. Biol Chem. 2001 Aug;382(8):1197-205. doi: 10.1515/BC.2001.150. Biol Chem. 2001. PMID: 11592401 - Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?
Fazioli F, Blasi F. Fazioli F, et al. Trends Pharmacol Sci. 1994 Jan;15(1):25-9. doi: 10.1016/0165-6147(94)90130-9. Trends Pharmacol Sci. 1994. PMID: 8140655 Review.
Cited by
- Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.
Nip J, Rabbani SA, Shibata HR, Brodt P. Nip J, et al. J Clin Invest. 1995 May;95(5):2096-103. doi: 10.1172/JCI117897. J Clin Invest. 1995. PMID: 7537755 Free PMC article. - Fibrinolysis protease receptors promote activation of astrocytes to express pro-inflammatory cytokines.
Pontecorvi P, Banki MA, Zampieri C, Zalfa C, Azmoon P, Kounnas MZ, Marchese C, Gonias SL, Mantuano E. Pontecorvi P, et al. J Neuroinflammation. 2019 Dec 6;16(1):257. doi: 10.1186/s12974-019-1657-3. J Neuroinflammation. 2019. PMID: 31810478 Free PMC article. - Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis.
Hu Z, Brooks SA, Dormoy V, Hsu CW, Hsu HY, Lin LT, Massfelder T, Rathmell WK, Xia M, Al-Mulla F, Al-Temaimi R, Amedei A, Brown DG, Prudhomme KR, Colacci A, Hamid RA, Mondello C, Raju J, Ryan EP, Woodrick J, Scovassi AI, Singh N, Vaccari M, Roy R, Forte S, Memeo L, Salem HK, Lowe L, Jensen L, Bisson WH, Kleinstreuer N. Hu Z, et al. Carcinogenesis. 2015 Jun;36 Suppl 1(Suppl 1):S184-202. doi: 10.1093/carcin/bgv036. Carcinogenesis. 2015. PMID: 26106137 Free PMC article. Review. - Downregulation of the urokinase-type plasminogen activator receptor through inhibition of translation by antisense oligonucleotide suppresses invasion of human glioblastoma cells.
Mohan PM, Lakka SS, Mohanam S, Kin Y, Sawaya R, Kyritsis AP, Nicolson GL, Rao JS. Mohan PM, et al. Clin Exp Metastasis. 1999;17(7):617-21. doi: 10.1023/a:1006779902978. Clin Exp Metastasis. 1999. PMID: 10845561 - Urokinase type plasminogen activator receptor expression in colorectal neoplasms.
Suzuki S, Hayashi Y, Wang Y, Nakamura T, Morita Y, Kawasaki K, Ohta K, Aoyama N, Kim SR, Itoh H, Kuroda Y, Doe WF. Suzuki S, et al. Gut. 1998 Dec;43(6):798-805. doi: 10.1136/gut.43.6.798. Gut. 1998. PMID: 9824607 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous